Literature DB >> 16417542

Quantitative MRI biomarkers of cognitive morbidity in temporal lobe epilepsy.

Tayo O Oyegbile1, Abhik Bhattacharya, Michael Seidenberg, Bruce P Hermann.   

Abstract

PURPOSE: To determine the relation between neuropsychological morbidity, quantitative magnetic resonance imaging (MRI) measures of whole brain structure, and clinical seizure factors reflecting epilepsy cause, course, and treatment.
METHODS: Quantitative MRI measurements of total (whole brain) cerebrospinal fluid (CSF) and gray- and white-matter volumes and clinical seizure features were examined in relation to summary indices of cognitive morbidity in 96 patients with temporal lobe epilepsy. MRI volumes were adjusted for intracranial volume (ICV), and cognitive scores were adjusted for age, education, and gender, based on a sample of 82 healthy controls.
RESULTS: Whole-brain volumes (gray, white, and CSF) were abnormal in chronic temporal lobe epilepsy patients compared with controls and were related significantly to neuropsychological morbidity, especially total CSF. Statistical modeling demonstrated that markers of total atrophy (CSF) was the primary mediator of the relation between clinical seizure variables and neuropsychological morbidity.
CONCLUSIONS: Quantitative measurements of overall brain abnormality (atrophy) in temporal lobe epilepsy are clinically meaningful markers that are associated with increased cognitive morbidity. These biomarkers appear to mediate the adverse effects of some clinical seizure variables on cognition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16417542     DOI: 10.1111/j.1528-1167.2006.00380.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  9 in total

1.  New evidence supports cognitive decline in temporal lobe epilepsy.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2007 Jan-Feb       Impact factor: 7.500

2.  Evaluation of corpus callosum morphometry in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.

Authors:  A Firat; A B Tascioglu; M D Demiryurek; S Saygi; K Karli Oguz; F I Tezer; M Hayran
Journal:  Surg Radiol Anat       Date:  2013-06-15       Impact factor: 1.246

3.  Thalamofrontal neurodevelopment in new-onset pediatric idiopathic generalized epilepsy.

Authors:  D T Pulsipher; K Dabbs; V Tuchsherer; R D Sheth; M A Koehn; B P Hermann; M Seidenberg
Journal:  Neurology       Date:  2011-01-04       Impact factor: 9.910

4.  Cortical thickness in childhood left focal epilepsy: Thinning beyond the seizure focus.

Authors:  Emanuel M Boutzoukas; Jason Crutcher; Eduardo Somoza; Leigh N Sepeta; Xiaozhen You; William D Gaillard; Gregory L Wallace; Madison M Berl
Journal:  Epilepsy Behav       Date:  2019-12-06       Impact factor: 2.937

5.  Thalamofrontal circuitry and executive dysfunction in recent-onset juvenile myoclonic epilepsy.

Authors:  Dalin T Pulsipher; Michael Seidenberg; Leslie Guidotti; Victoria N Tuchscherer; Jared Morton; Raj D Sheth; Bruce Hermann
Journal:  Epilepsia       Date:  2009-01-17       Impact factor: 5.864

Review 6.  The use of neuroimaging to study behavior in patients with epilepsy.

Authors:  Carrie R McDonald
Journal:  Epilepsy Behav       Date:  2007-12-19       Impact factor: 2.937

7.  Distinct regional atrophy in the corpus callosum of patients with temporal lobe epilepsy.

Authors:  Bernd Weber; Eileen Luders; Jennifer Faber; Sabine Richter; Carlos M Quesada; Horst Urbach; Paul M Thompson; Arthur W Toga; Christian E Elger; Christoph Helmstaedter
Journal:  Brain       Date:  2007-08-29       Impact factor: 13.501

Review 8.  The emerging architecture of neuropsychological impairment in epilepsy.

Authors:  Bruce P Hermann; Jack J Lin; Jana E Jones; Michael Seidenberg
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

9.  MicroRNA expression profiles in chronic epilepsy rats and neuroprotection from seizures by targeting miR-344a.

Authors:  Xixia Liu; Yuhan Liao; Xiuxiu Wang; Donghua Zou; Chun Luo; Chongdong Jian; Yuan Wu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-31       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.